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Abstract 
Aim: Patients with classic Congenital Adrenal Hyperplasia (CAH) have poor health 
outcomes. In the absence of a comprehensive observational study, this manuscript provides a 
model to estimate the lifetime disease burden of adults with classic CAH.  
Methods: The model, built in Excel, comprises sub-domains addressing the health 
consequences of CAH, and synthesises evidence from clinical and epidemiological studies on 
health outcomes.  
Results: The model estimates that adults with classic CAH will implement “sick day rules” 
(doubling or tripling glucocorticoid and/or use of parenteral therapy) 171 times over their 
lifetime, and attend hospital for adrenal crisis on 11 occasions. In a population of 1,000, over 
200 will die of a condition complicated by adrenal crisis resulting, on average, in a loss of 7 
years of life. CAH patients may also suffer from excess CVD events. Treatment with 
glucocorticoids almost doubles the risk of bone fractures in CAH patients compared to the 
general population, leading on average to an additional 0.8 fractures per CAH patient over 
their lifetime.   
Conclusions: The disease burden model highlights gaps in evidence, particularly regarding 
intensity of care and adrenal crisis, and the relationship between control of CAH and risks of 
CVD, osteoporosis, diabetes and infertility. The model can be used for research on the impact 
of new clinical pathways and therapeutic interventions in terms of clinical events and cost. 
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Introduction 
Congenital Adrenal Hyperplasia (CAH) is the commonest congenital endocrine disorder, 
arising from defective steroidogenesis 1. The most frequent mutation is in the gene encoding 
21-hydroxylase (21-OH) resulting in failure of cortisol synthesis and consequently increased 
pituitary adrenocorticotropic hormone (ACTH) release, which in turn promotes over-
production of 17-hydroxyprogesterone (17-OHP), progesterone, and adrenal androgens – 
termed classic CAH. Patients with CAH due to 21-OH deficiency have two major problems: 
cortisol deficiency and androgen excess. In addition, many patients also have 
mineralocorticoid deficiency as 21-OH mediates a key step in aldosterone synthesis. The 
clinical classification of 21-OH deficiency is based on the severity of mutations. The most 
severe classic form occurs in about 1 in 15,000 births 2. The classic form usually presents 
early in life or at neonatal screening and comprises salt wasting and simple virilising 
subgroups based on whether the severity of aldosterone deficiency causes a salt-wasting 
hypotensive crisis in the new-born.  Classic CAH is characterised by sexual ambiguity at 
birth in females, and by precocious puberty, short stature and fertility problems in both males 
and females. 
 
Treatment of CAH is by glucocorticoid and mineralocorticoid replacement. However, this 
presents a challenge as no current glucocorticoid regimen replicates the normal circadian 
rhythm of cortisol. There is no consensus on what glucocorticoid regimen to use in adults 
with CAH and patients receive a variety of treatments including hydrocortisone, 
prednisolone, prednisone, and dexamethasone give in a circadian or reverse circadian fashion 
3, 4. As a result glucocorticoid under- and over-treatment is a risk, and is linked to 
complications including adrenal crisis, obesity, hyperlipidaemia, hypertension, cardiovascular 
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disease (CVD) and reduced bone mineral density (BMD) 5. Health-related quality of life 
(HRQoL) has been variously reported reduced in some studies and normal in others 3, 6, 7. 
The need for regular physician visits to manage and adjust treatment, the risk of adrenal crisis 
(AC), and the long-term impacts of both CAH symptoms and glucocorticoid therapy lead to a 
considerable burden on the health service. This is the first study to model and estimate the 
disease burden and excess mortality associated with classic CAH in adults.  
 
Methods and Model 
Model Overview 
The model computes Life Years (LYs) and Quality Adjusted Life Years (QALYs) for adults 
with classic CAH compared to the general population. The QALY is a measure of health that 
attempts to capture mortality and morbidity. The impact of morbidity on the patient is 
measured in terms of health-related quality of life (HRQoL), using a single scale anchored on 
one (which represents perfect health) and zero (which represents death).  QALYs are then 
calculated by multiplying the HRQoL value with the length of life spent in that health state, 
for example, 10 years at 0.5, produces 5 QALYs. This approach can be extended to estimate 
the QALYs across complex chronic disease profiles.  Whilst the QALY is too crude to be 
used clinically, QALYs can be used as a measure of disease burden, or combined with costs 
to estimate cost-effectiveness 8.  International guidelines for cost-effectiveness recommend 
the use of QALYs for the assessment of patient outcomes 9, and this has been followed by 
similar recommendations at the national level in several countries, including the UK. The 
core model addresses the direct effect of CAH on patients including HRQoL and mortality 
associated with adrenal crisis (AC). The sub-models examine co-morbidities associated with 
CAH (Figure 1).  
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The models are life tables tracking health-related events, LYs and QALYs each year for men 
and women separately from age 18 years for life. National general population mortality rates 
are applied, adjusted for increases in fatalities from AC and CVD in the separate sub-models 
10. Baseline age-related utility for the general population (measured with the EQ-5D scale) 
was calculated using published evidence 11. Model parameters were taken from the literature, 
where available.  
 
Model Sub-domains 
Direct CAH burden including Adrenal Crisis: Studies have reported reduced QoL in CAH 
adults, in particular reduced general health and vitality 3, 6, 12.  EQ-5D utility values were 
derived from the SF-36 scores for CAH and the general population reported in the CaHASE 
study 3, 13.  
 
During illness CAH patients need to increase their dose of glucocorticoid to meet the 
increased demand for adrenal steroids, i.e. invoke “sick day rules”. If this is delayed, or not 
done, patients are more likely to have an AC requiring attendance at hospital and parenteral 
steroids, and a proportion of patients will die during an AC. There is limited data available 
regarding care for AC, so some parameters have had to be estimated by a clinical expert 
(Author RJR). Sensitivity analysis was conducted on these parameters. All parameter values 
are shown in Table 1.  
 
The rate of AC was reported as 0.066 per patient-year in patients with primary adrenal 
insufficiency 14. Ninety-five percent confidence limits were estimated from the reported 
number of AC and patient-years (0.058, 0.074). A similar rate of AC (similarly defined) was 
reported in CAH patients 15, but the rate fell to 0.038 per patient year when the initial salt-
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wasting crises which precipitated the diagnosis in infants were excluded. This latter figure is 
used in sensitivity analysis. 
 
Cardiovascular Disease (CVD): CAH patients may have increased Body Mass Index 
(BMI), blood pressure and cholesterol compared to the general population, all known risk 
factors for CVD 3, 16. A Swedish study reports CVD mortality in Addison’s Disease to be 
approximately twice that for the general population, although no excess CVD mortality was 
found in a similar Norwegian population 17, 18. The model uses data from the general 
population for CVD events and death, and applies to these a relative risk (RR) of CVD events 
for CAH patients, thus yielding estimates of CVD event rates for CAH patients. The RR of 
CVD in CAH patients was estimated using an approximation of the QRISK2 CVD risk 
equation using mean differences in BMI and systolic blood pressure between CAH and the 
general population from the CAHASE study 3, 16. This yielded a 10% increase in risk of CVD 
events for women. Note for men in the CaHASE study there was no significant difference in 
BMI or blood pressure between CAH patients and the general population so the baseline 
assumption is no increased CVD risk for men. For maximum value sensitivity analysis the 
results of Bergthorsdottir (2006)17 were used: RR of CVD of 2.31 for women and 1.97 for 
men. For the minimum scenario no increased risk of CVD arising from CAH was assumed. 
The model includes incident angina, stroke and MI events, deaths from stroke and MI, as well 
as all CVD deaths. CVD age-related event rates for the general population were taken from 
national data 19, 20 (a supplementary table is available summarising this data). A conservative 
approach was taken to estimate the HRQoL reductions due to CVD events: the loss of 
HRQoL due to stroke or MI was applied in the year of the event only leading to an 
underestimate of total QALY loss associated with these events 21.  
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Obesity: Women with CAH have an average BMI of 6.2 kg/m2 greater than the general 
population of similar age 3. Obesity has a negative effect on HRQoL independent of the 
associated chronic illnesses 22. High BMI particularly affects pain and mobility. Using data 
from Macran (2004)22 a linear relationship was derived showing a loss of 0.0033 in utility for 
every unit increase in BMI (kg/m2) for BMI greater than 21kg/m2 in a population of median 
age 46 years. For men there was no independent relationship between BMI and utility, and no 
difference in in BMI between men with CAH and the general population 3, 22.  
 
Bone Fractures: Glucocorticoid treatment is known to reduce BMD and put patients at 
increased risk of fractures, with fracture risk associated with dose 23. The lifetime number of 
fractures was estimated for people with CAH and the general population (a supplementary 
table is available summarising this data). Baseline fracture incidence by age for non-vertebral 
and hip fractures was taken from the literature 23, 24. Similar data was not identified for 
vertebral or forearm fractures: it was assumed that the relationship between fracture incidence 
and age is the same for forearm fractures as for all non-vertebral fractures, and that the 
relationship between age and fracture incidence for vertebral fractures is similar to hip 
fractures, adjusted for absolute incidence in both cases 23. It was assumed the mean 
equivalent hydrocortisone dose for CAH adults was 29.6mg per day 3. Curves were fitted to 
data from van Staa 25 to establish the RR of fractures by glucocorticoid dose (daily 
hydrocortisone dose equivalent mg/day = DD):  
All fracture RR = -0.00009 * DD2 + 0.267 * DD + 1 
 
Femur/hip fracture RR = -0.0002 * DD2 + 0.0343 * DD + 1 
 
Vertebral fracture RR = 0.0702 * DD + 1 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
EQ-5D utility values were from Stevenson (2007) 26. As no utility for wrist fracture was 
reported, that for “other” fractures was used as this was the most conservative (highest). 
Excess mortality from hip fractures was not considered, as mortality directly attributable to 
fractures is relatively low, especially in younger age groups (estimated 2% age 50-60 years, 
rising to 16% age 90 years or more) 26. 
 
Fertility: CAH affects fertility in both men and women. In the CaHASE study 25% of 
women attempted to conceive, of which 54% were successful indicating that, of all women 
with classic CAH, 13.5% conceived, and 11.5% sought fertility and failed 3. In the same 
study, 37% of men attempted to conceive, of which 67% were successful, so 25% of all men 
with classic CAH fathered children and 12% sought fertility and failed 3. However, data on 
fertility choices of both CAH patients and the general population is limited, and therefore it is 
included as a sensitivity analysis only. The NICE clinical guideline on fertility quotes figures 
indicating that 92% of women in the general population will conceive after two years and 
93% after three years 27, 28. However a study of infertility in UK general practice reports a 
rate of 5.9 per 1000 person-years, suggesting a far lower proportion of women 
(approximately 0.6%) seeking help for infertility 29. The greater estimate of 7% unwanted 
infertility is used in the model 27, adjusted for the proportion of couples seeking help for 
infertility who already have at least one child (41% 30): to be consistent with the scenario for 
CAH patients only totally infertile couples in the general population are considered. 
Outcomes from a specialist fertility clinic indicate a 51% success rate within 5 years, with 
approximately half of all patients receiving active treatment 30.  All the data discussed refers 
to women: it has been assumed that men in the general population are similarly affected by 
infertility.  
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There is little information on the effect of unwanted infertility on HRQoL. The utility 
decrement (0.07) was taken from the NICE fertility guideline and applied in the same way; 
that is a constant decrement applied for life 27. Note this may overestimate QALY losses from 
infertility if the utility decrement decreases with time. In the absence of other data it is 
assumed that the utility decrement is the same for men. The utility decrement is applied from 
the average age at which the general population has their first child (Table 2). 
 
Results 
Core model - CAH  
The model estimates that on average adults with CAH will implement “sick day rules” 
(doubling or tripling glucocorticoid and/or use of parenteral therapy) 171 times over their 
lifetime, and attend hospital for AC on 11 occasions. In a population of 1,000 over 200 will 
die of a condition complicated by AC resulting, on average, in a loss of 7.3 years of life, or 
9.0 QALYs (Figure 2 and Table 3).  
 
It can be seen that the direct effects of CAH and associated AC, are the main cause of excess 
morbidity and mortality in CAH adults. The comorbidities do not affect all CAH patients, and 
CVD and bone fractures affect people mostly later in life. When comorbidities are considered 
the survival difference between CAH adults and the general population is 7.4 years, or taking 
into account the effect on HRQoL, 10.2 QALYs. If the (uncertain) effects of infertility are 
included the difference in QALYs increases to 10.6.  
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The effects of CVD are modest, but for the baseline model an increased risk of only 10% was 
estimated, and for women only. Nevertheless, in a population of 1000 CAH women they will 
experience an estimated additional 11 MI, 41 strokes and 17 CVD deaths compared to the 
general population.  
 
Obesity (independent of CVD effects) and bone fractures are assumed to affect HRQoL and 
not survival, and therefore have no effect on LYs. Nevertheless, the estimated effect of 
obesity on women’s QALYs is not negligible: with an average BMI of 6.2 kg/m2 greater than 
the general population of similar age 3, the estimated reduction in utility is 0.02 for women 
aged 46. Over the adult lifetime this leads to a loss of 1.3 QALYs for CAH women compared 
to the general population.  
 
The incidence of fractures is approximately doubled in persons with CAH compared to the 
general population (Figure 3). For women this means an average of one additional fracture 
over their lifetime; for men 0.7 fractures. Despite this the estimated effect of additional bone 
fractures on QALYs is relatively small (Table 3), affecting people mainly in old age.  
 
Sensitivity analysis 
The sensitivity analysis focused on the core CAH/AC model as almost all the difference in 
LYs and QALYs between CAH adults and the general population arise from the direct effects 
of CAH. A sensitivity analysis on the RR of CVD for CAH adults is also presented given the 
uncertainty and potential effect of this parameter on outcomes (Table 3).  
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The parameter that contributes to the greatest uncertainty in the results is the average number 
of times a year CAH adults need to implement “sick day rules”. No data was available for 
this parameter, which was estimated to be between one and six times per year, with a baseline 
value of three. The estimated number of deaths from conditions exacerbated by AC is related 
to this parameter as the probability of death from AC is applied to the number of patients 
admitted as inpatients for AC, which in turn depends on the number needing to implement 
“sick day rules”. The other parameters in the CAH/AC module contribute to a similar level of 
uncertainty: all, with the exception of CAH utility, contributing to the estimated number of 
deaths from AC.    
 
A  10% increase in RR of CVD events for women only is estimated for the baseline scenario: 
the maximum, based on observational evidence, uses a RR of approximately two 17. The 
resulting additional CVD mortality reduces survival in CAH adults by approximately two 
years.  
 
Discussion 
Adults with CAH experience reduced HRQoL and reduced survival. In recent years there has 
been a growing literature on the epidemiology of the condition but to our knowledge no 
previous attempt has been made to estimate the overall lifetime burden of CAH, including 
associated co-morbidities. Our results show that despite the many co-morbidities experienced 
by adults with CAH, it is CAH itself, and in particular the mortality arising from conditions 
exacerbated by AC, which results in average survival being 7 years less than for the general 
population. Consideration of the effect of reduced lifelong HRQoL gives an estimated 
reduction of 9 QALYs. There is uncertainty in all the model parameters associated with this 
estimate, and both the number of times a year patients implement sick day rules and the 
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proportion of patients experiencing AC who are admitted as inpatients were estimated by the 
authors. The effect of the uncertainty in all the CAH/AC parameters on the results (LY and 
QALYs) are of a similar order of magnitude, giving a range in estimated reduction in survival 
of between 2 and 13 years, and 5 to 14 QALYs. 
 
CVD has a very limited effect on survival and QALYs in the baseline model: the effect of 
CAH on CVD is uncertain as life-saving glucocorticoid therapy was only introduced in the 
1950s so there are few patients in their sixties. An increased risk of just 10% was applied for 
women only: CAH men in the CAHASE study did not have increased BMI or systolic blood 
pressure compared to the general population. The baseline analysis assumes that the 
relationship between risk factors and CVD events in the CAH population is the same as that 
for the general population. In fact there is some evidence that the CVD burden in CAH may 
be much greater 17.  Sensitivity analysis using an RR of approximately two for CVD risk for 
both men and women 17, suggests CVD mortality may reduce survival in CAH adults by up 
to two years. Mortality is calculated separately in the CAH core model and CVD sub-model 
so the mortality reductions are not additive. The effect of CVD morbidity is underestimated 
as the disutility of CVD events is only applied in the year of occurrence. 
 
We did not include diabetes in our model as the relationship between markers of insulin 
sensitivity and glucocorticoid treated CAH patients is complex. Patients with CAH and 
adrenal insufficiency (AI) who are under replaced with glucocorticoid are at risk of 
hypoglycaemia and this is a presenting feature of AI in neonates and children as cortisol 
reduces insulin sensitivity. The physiological rise in the early morning hours reduces insulin 
sensitivity and protects from nocturnal hypoglycaemia and replacement of cortisol in patients 
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with CAH has a similar effect with a rise in HOMA-IR 31. Thus, the use of change in HOMA-
IR as a risk factor for diabetes is not appropriate in CAH.   
 
The effects of long term glucocorticoid treatment on fractures is well established, with risk 
increasing with higher doses 25. This relationship was used to model the likely increase in 
fractures in adults with CAH.  A recent paper has examined fractures in patients with CAH 
and found no-statistically significant relationship with GC exposure, although the sample size 
was small 32.  However, the authors did find an increase in fractures associated with classic 
CAH compared to non-classic CAH, which suggests an increased fracture risk over that of 
the general population. This may suggest an increased risk independent of GC exposure; 
however, there is insufficient evidence at this time for this to be reliably modelled. 
 
Structural and hormonal problems inhibit fertility in CAH adults, and unwanted infertility has 
been shown to reduce HRQoL, at least in women 33. Estimation of the consequences on 
QALYs of unwanted infertility resulting from CAH is uncertain as data is limited for the 
general population, especially men, as well as for CAH adults. Data reported in the CAHASE 
study was used to estimate unwanted infertility in the CAH population, but many subjects 
were of an age where their fertility choices may not have been final 3. Also the data may 
underestimate latent desire for fertility as CAH patients may be discouraged from considering 
fertility.  
 
This is the first attempt to model the overall disease burden of CAH and naturally has the 
limitations of using historical cross-sectional data from different populations. The model is 
relatively simple, with a separate lifetable for each co-morbidity resulting in potential 
overestimation of the total effects when the results of each are summed. However, given the 
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dominance of the direct effects of CAH/AC on outcomes this has little effect on the results. 
Caution needs to be taken in interpretation of other published models when applied to CAH; 
however we have had to use these in the absence of validated models in CAH. For example, 
our estimates of bone fractures come from the use of glucocorticoids as anti-inflammatory 
agents whereas in CAH it is substitution therapy and there may be a balancing effect of 
excess androgens. Similarly obesity has a complex relationship with fractures and bone 
density and this would be expected to be more complex in the face of androgen and 
glucocorticoid imbalance.  
 
As a generic measure of health, QALYs are used to capture the effects of treatments across 
many conditions.  Their ability to combine mortality and morbidity effects makes them useful 
for complex conditions, such as those of the endocrine system.  The use of QALYs and cost-
effectiveness analysis within diabetes has shown how multiple clinical effects can be 
captured and evaluated within this framework.  However, the methods by which the HRQoL 
of patients is captured have drawn criticism as they have been found to be insensitive to 
clinical change in many situations.  In our study, the HRQoL effects were measured using the 
EQ-5D descriptive system and scoring algorithm34, yet the EQ-5D doesn’t directly measure 
vitality which is an important feature of CAH.  As such, the HRQoL scores and QALYs may 
underestimate the impact of CAH on health.  Despite these potential problems, an alternative 
summary measure of burden of disease that is also applicable to cost-effectiveness analysis is 
not available. 
 
Development of the model has highlighted gaps in the evidence, particularly intensity of care 
for AC, and the relationship between control of CAH and risks of CVD, osteoporosis and 
infertility. This modelling approach has the potential to assess the long-term patient effects of 
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therapeutic changes via their impact on the estimated model parameters, for example, number 
of sick day rules, BMI, systolic blood pressure and steroid use. 
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Table and Figure Legends: 
 
Table 1: Data used to estimate lifetime CAH burden 
Table 2: Fertility model parameters 
Table 3: Differences in LYs and QALYs between CAH and the general population, base 
case and sensitivity analysis 
 
Figure 1: Diagram of the conceptual model 
Figure 2: Effect of CAH on survival 
Figure 3: Lifetime average number of fractures per person 
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Tables 
Table 1: Data used to estimate lifetime CAH burden 
  Mean Max Min Source 
Sick day rules per year 3 6 1 Clinical expert (RJR) 
Hospital for IV hydrocortisone per 
year 0.066 0.074 0.038 Hahner 2010, Reisch 2012   
Of which inpatient  0.75 1 0.25 Clinical expert (RJR) 
P(death) after inpatient admission 
for AC 0.025 0.032 0.005 Clinical expert (RJR) , Rushworth 2014 
Utility multiplier CAH 0.93 0.97 0.89 
Derived from CaHASE (Arlt 2010, Rowen 
2009) 
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Table 2: Fertility model parameters 
Item   Mean Source 
CAH parameters       
CAH seek fertility 
women 0.25 CaHASE Arlt 2010 
men 0.37   
CAH succeed (of those 
seeking) 
women 0.54 CaHASE Arlt 2010 
men 0.67   
General population 
parameters       
Unwanted infertility all 0.07 NICE 2013 
Proportion no previous child all 0.59 Pandey 2014 
Successful outcome  all 0.51 Pandey 2014 
All       
Mean age 1st child women 27.9 ONS fertility 2013 
  men 30.8 ONS fertility 2013 
Utility decrement infertility  women 0.07 NICE 2013 
  men 0.07 Assumption 
Table 3: Differences in LYs and QALYs between CAH and the general population, base 
case and sensitivity analysis 
  Life Years QALYs 
Item  Women Men All Women Men All 
Base case 
CAH/AC  -7.54 -6.77 -7.25 -9.22 -8.75 -9.04 
Sensitivity 
CAH Utility max - - - -7.35 -6.92 -7.18 
min - - - -11.10 -10.58 -10.90 
AC sick day 
rules/year 
max -13.94 -12.56 -13.42 -13.97 -13.20 -13.68 
min -2.66 -2.38 -2.55 -5.62 -5.38 -5.53 
Hospital for IV 
hydrocortisone/year 
max -8.38 -7.53 -8.06 -9.84 -9.33 -9.65 
min -4.50 -4.03 -4.32 -6.97 -6.65 -6.85 
Of which inpatient max -9.79 -8.80 -9.42 -10.89 -10.31 -10.67 
min -2.66 -2.38 -2.55 -5.62 -5.38 -5.53 
P(death) following 
inpatient admission 
max -9.44 -8.49 -9.08 -10.63 -10.06 -10.41 
min -1.61 -1.44 -1.55 -4.85 -4.66 -4.78 
Base case 
CVD  -0.19 0.00 -0.12 -0.14 0.00 -0.09 
Sensitivity 
RR of CVD max -2.17 -2.13 -2.16 -1.62 -1.67 -1.64 
min 0.00 0.00 0.00 0.00 0.00 0.00 
Base case 
Obesity  - - - -1.29 0.00 -0.80 
Bone fractures  - - - -0.39 -0.17 -0.30 
Total  -7.73 -6.77 -7.37 -11.04 -8.92 -10.24 
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